This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vivian Xie
5 Jun 2024

Novo Nordisk launches 'Power of Wegovy' national campaign

Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States.

Novo Nordisk, the pharmaceutical giant behind drug products Wegovy and Ozempic, have announced the launch of their campaign ‘The Power of Wegovy’ in an effort to educate on the clinical data of Wegovy 2.4 mg injection.  

Wegovy is Novo Nordisk’s blockbuster injectable for the treatment of obesity and weight-related medical complications. Originally sold as Ozempic for the treatment of diabetes, Wegovy is a semaglutide injection for chronic weight management and reduced the risk of stroke, heart attack, and/or death in overweight or obese patients when used in tandem with low-calorie diets and exercise. Semaglutide injections like Wegovy and Ozempic mimic the GLP-1 hormone released in response to eating by the gastrointestinal (GI) tract. This helps the body produce more insulin and reduces blood glucose. In higher amounts, GLP-1 can reduce appetite and create feelings of fullness. 

The Power of Wegovy campaign will focus on reinforcing the FDA’s approval of Wegovy among obese and overweight patients as well as the general public. The campaign follows an update to the approval of Wegovy by the FDA, which removed body mass index (BMI) descriptors from weight-management indications and introduced new cardiovascular risk reduction indications. “Diverse representation in health care campaigns can play a significant role in patients feeling seen, heard, and understood, especially in stigamtized space like obesity, which we’ve been engaged in for more than 2 decades,” commented Tejal Vishalpura, Senior Vice President, Commercial Strategy and Marketing at Novo Nordisk. “The Power of Wegovy is committed to representing a cross-section of unique perspectives at this cultural inflection point in society, especially when the connection between obesity, cardiovascular risk, and the importance of patient-centred care is so much a part of the public discourse.” 

The Power of Wegovy campaign hopes to provide diverse and unique portrayals of individuals who have partnered with their healthcare professionals throughout their weight-management journey, while providing information and educating on the clinical data for Wegovy. With these personal stories, Novo Nordisk aims to address stigma in weight management and obesity treatments. 


Novo Nordisk launches national Wegovy campaign, Power of Wegovy [Accessed June 5, 2024]  

Vivian Xie
Editor - Custom Content

Related News